E. A. Căruntu *, Violeta Molagic **
* Dr. Florin Alexandru Căruntu – șef de lucrări UMF “Carol Davila” București, Clinica de Boli lnfecțioase, lnstitutul de Boli lnfecțioase “Prof Dr. Matei Balș”
** Dr. Violeta Molagic – Medic specialist boli infecțioase, lnstitutul de Boli lnfecțioase “Prof Dr. Matei Balș”
Abstract
The HBV infection continues to remain in the world ajor problem of public health. Because none of the a m antiviral agent are not able to causes the complete eradi cation of the HBV, the control of replication became an important target in antiviral therapy. Recently, FDA approved the Entecavir utilization in the chronic hepatitis treatment with HVB. This is a nucleosidic analogue, which has fol lowing advantages: Higher potency in decreasing of viral loading of HVB, orally administration, excellent tolerance, the administration in the cases of failure to Lamivudine. The performed studies have demonstrated the superiority of ETV against the utilization of Lamivudine. The recom mended doses are: 0.5 mg daily in the case of inborn patients to analogic nucleosidic analogue and 1mg daily in the pretreated cases with Lamivudine.